Key PointsAbbVie is aggressively diversifying its pipeline to mitigate the revenue impact from its loss of patent exclusivity on Humira.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.